India’s IPCA says Global Fund stops buying its anti-malarial drugs

India’s IPCA Laboratories Ltd said on Thursday that the Global Fund to Fight AIDS, Tuberculosis and Malaria, would no longer buy the company’s anti-malarial treatments after a U.S. regulatory warning about quality lapses at its factories. IPCA said in February that the U.S. Food and Drug Administration had issued it with a warning letter outlining manufacturing quality lapses observed at three of its Indian factories. The Global Fund will no longer source Artemisinin-based Combination Therapy (ACTs), an anti-malarial treatment, from IPCA following a “risk consideration exercise”, the drugmaker said.
Go to Source

Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change

Saunders gives an interview on the floor of the NYSEU.S. drugmaker Pfizer Inc and Ireland-based Allergan Plc walked away from their $160 billion merger on Wednesday, a major win for President Barack Obama, who has been pushing to curb deals in which companies move overseas to cut taxes. Pfizer said the decision was driven by new U.S. Treasury rules aimed at such deals, called inversions. The merger would have allowed New York-based Pfizer to cut its tax bill by an estimated $1 billion annually by domiciling in Ireland, where tax rates are lower.

Go to Source

1 7 8 9 10 11